The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Increased Permeability of the Blood-Brain Barrier to Chemotherapy in Metastatic Brain Tumors: Establishing a Treatment Paradigm
Abstract
There is no accepted standard of care for the chemotherapy treatment of metastatic brain tumors, which has been generally limited to lipophilic alkylators, which may not have efficacy against the tumor that metastasized to the brain. More than 50% of chemotherapy agents are natural product drugs, which are rarely used in the treatment of metastatic brain tumors because they are thought to not cross the blood-brain barrier (BBB). A major protein constituent in the BBB is P-glycoprotein (P-gp), which pumps natural product chemotherapy drugs and toxins out of the CNS. However, P-gp expression in the neovasculature of metastatic brain tumors is similar to the P-gp expression in the neovasculature of the primary, extracranial tumor. In contrast, gliomas have higher P-gp expression in their neovasculature, similar to the greater intrinsic expression of P-gp in normal brain vasculature. This decreased immunohistochemical expression of P-gp in the neovasculature of metastatic tumors, as well as our recent pharmacologic demonstration of increased tissue concentrations of paclitaxel in metastatic brain tumors compared with gliomas, support the idea that the choice of chemotherapy agents should be based on the histologic origin of the metastatic brain tumor and not on the lipophilicity of the drug. Our hypothesis is that metastatic brain tumors from tumors with intrinsically low P-gp expression (eg, lung, melanoma, and untreated breast) may be more permeable to natural product chemotherapy drugs than gliomas. This information could lead to a paradigm shift in the use of natural product drugs for metastatic brain tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Vessel Cooption, Regression, and Growth in Tumors Mediated by Angiopoietins and VEGF
Holash, J., Maisonpierre, P. C., Compton, D., Boland, P., Alexander, C. R., Zagzag, D., Yancopoulos, G. D., & Wiegand, S. J. (1999) · Science · doi:10.1126/science.284.5422.1994 · Cited by 2,195
Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,966
VEGF enhances angiogenesis and promotes blood–brain barrier leakage in the ischemic brain
Zhang, Z. G., Zhang, L., Jiang, Q., Zhang, R., Davies, K., Powers, C., Bruggen, N. V., & Chopp, M. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9369 · Cited by 1,296
Maxwell, P. H., Dachs, G. U., Gleadle, J. M., Nicholls, L. G., Harris, A. L., Stratford, I. J., Hankinson, O., Pugh, C. W., & Ratcliffe, P. J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.15.8104 · Cited by 1,084
Cordon-Cardo, C., O'Brien, J. P., Boccia, J., Casals, D., Bertino, J. R., & Melamed, M. R. (1990) · Journal of Histochemistry & Cytochemistry · doi:10.1177/38.9.1974900 · Cited by 1,062
Brain metastases: epidemiology and pathophysiology
Gavrilovic, I. T., & Posner, J. B. (2005) · Journal of Neuro-Oncology · doi:10.1007/s11060-004-8093-6 · Cited by 975
Distribution of Brain Metastases
Delattre, J. Y., Krol, G., Thaler, H. T., & Posner, J. B. (1988) · Archives of Neurology · doi:10.1001/archneur.1988.00520310047016 · Cited by 778
Brain metastases: Histology, multiplicity, surgery, and survival
Nussbaum, E. S., Djalilian, H. R., Cho, K. H., & Hall, W. A. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19961015)78:8<1781::aid-cncr19>3.0.co;2-u · Cited by 679
Outwitting the Blood-Brain Barrier for Therapeutic Purposes: Osmotic Opening and Other Means
KrolI, R. A., Neuwelt, E. A., & Neuwelt, E. A. (1998) · Neurosurgery · doi:10.1097/00006123-199805000-00082 · Cited by 581
Law, M., Cha, S., Knopp, E. A., Johnson, G., Arnett, J., & Litt, A. W. (2002) · Radiology · doi:10.1148/radiol.2223010558 · Cited by 571
The seed and soil hypothesis: vascularisation and brain metastases
Fidler, I. J., Yano, S., Zhang, R.-D., Fujimaki, T., & Bucana, C. D. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(01)00622-2 · Cited by 432
Dietrich, W. D., Busto, R., Halley, M., & Valdes, I. (1990) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199009000-00004 · Cited by 371
Earnest, F., Kelly, P. J., Scheithauer, B. W., Kall, B. A., Cascino, T. L., Ehman, R. L., Forbes, G. S., & Axley, P. L. (1988) · Radiology · doi:10.1148/radiology.166.3.2829270 · Cited by 370
Agarwala, S. S., Kirkwood, J. M., Gore, M., Dreno, B., Thatcher, N., Czarnetski, B., Atkins, M., Buzaid, A., Skarlos, D., & Rankin, E. M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.044 · Cited by 360
Lum, B. L., Kaubisch, S., Yahanda, A. M., Adler, K. M., Jew, L., Ehsan, M. N., Brophy, N. A., Halsey, J., Gosland, M. P., & Sikic, B. I. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.10.1635 · Cited by 299
(2000) · PubMed · Cited by 295
Yano, S., Shinohara, H., Herbst, R. S., Kuniyasu, H., BUCANA, C. D., Ellis, L. M., Davis, D. W., McConkey, D. J., & Fidler, I. J. (2000) · PubMed · Cited by 247
Sze, G. K., Milano, E., Johnson, C., & Heier, L. (1990) · PubMed Central · Cited by 240
Franciosi, V., Cocconi, G., Michiara, M., Di Costanzo, F., Fosser, V., Tonato, M., Carlini, P., Boni, C., & Di Sarra, S. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990401)85:7<1599::aid-cncr23>3.0.co;2-# · Cited by 240
A Phase II Trial of Temozolomide for Patients with Recurrent or Progressive Brain Metastases
Abrey, L. E., Olson, J. D., Raizer, J. J., Mack, M., Rodavitch, A., Boutros, D. Y., & Malkin, M. G. (2001) · Journal of Neuro-Oncology · doi:10.1023/a:1012226718323 · Cited by 230
Lee, T.-H., Avraham, H. K., Jiang, S., & Avraham, S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210063200 · Cited by 214
Provias, J., Claffey, K., delAguila, L., Lau, N., Feldkamp, M., & Guha, A. (1997) · Neurosurgery · doi:10.1097/00006123-199705000-00027 · Cited by 207
Allen, J. D., Brinkhuis, R. F., van Deemter, L., Wijnholds, J., & Schinkel, A. H. (2000) · PubMed · Cited by 200
Zhang, R. D., Price, J. E., Fujimaki, T., Bucana, C. D., & Fidler, I. J. (1992) · PubMed Central · Cited by 186
Dobrogowska, D. H., Lossinsky, A. S., Tarnawski, M., & Vorbrodt, A. W. (1998) · Journal of Neurocytology · doi:10.1023/a:1006907608230 · Cited by 180
Kemper, E. M., Boogerd, W., Thuis, I., Beijnen, J. H., & van Tellingen, O. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2004.04.001 · Cited by 177
Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases
Christodoulou, C., Bafaloukos, D., Kosmidis, P., Samantas, E., Bamias, A., Papakostas, P., Karabelis, A., Bacoyiannis, C., & Skarlos, D. V. (2001) · Annals of Oncology · doi:10.1023/a:1008354323167 · Cited by 174
Predilection of brain metastasis in gray and white matter junction and vascular border zones
Hwang, T.-L., Close, T. P., Grego, J. M., Brannon, W., & Gonzales, F. F. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960415)77:8<1551::aid-cncr19>3.0.co;2-z · Cited by 159
Advani, R., Saba, H. I., Tallman, M. S., Rowe, J. M., Wiernik, P. H., Ramek, J., Dugan, K., Lum, B., Villena, J., Davis, E., et al. (1999) · Blood · doi:10.1182/blood.v93.3.787 · Cited by 158
Rowinsky, E. K., Smith, L., Wang, Y. M., Chaturvedi, P. R., Villalona, M. A., Campbell, E., Aylesworth, C., Eckhardt, S. G., Hammond, L. A., Kraynak, M. A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.2964 · Cited by 146
Multidrug Resistance in Brain Tumors: Roles of the Blood–brain Barrier
Régina, A., Demeule, M., Laplante, A., Jodoin, J., Dagenais, C., Berthelet, F., Moghrabi, A., & Béliveau, R. (2001) · Cancer and Metastasis Reviews · doi:10.1023/a:1013104423154 · Cited by 141
Overexpression of ADAM9 in Non-Small Cell Lung Cancer Correlates with Brain Metastasis
Shintani, Y., Higashiyama, S., Ohta, M., Hirabayashi, H., Yamamoto, S., Yoshimasu, T., Matsuda, H., & Matsuura∥, N. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3235 · Cited by 139
Do anticancer agents reach the tumor target in the human brain?
Donelli, M. G., Zucchetti, M., & D’Incalci, M. (1992) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00686291 · Cited by 139
Bernardo, G. D., Cuzzoni, Q., Strada, M. R., Bernardo, A., Brunetti, G., Jedrychowska, I., Pozzi, U., & Palumbo, R. (2002) · Cancer Investigation · doi:10.1081/cnv-120001173 · Cited by 134
A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors
Stewart, D. J. (1994) · Journal of Neuro-Oncology · doi:10.1007/bf01052723 · Cited by 131
Cortés, J., Rodríguez, J., Aramendía, J. M., Salgado, E., Gúrpide, A., García‐Foncillas, J., Aristu, J., Claver, A., Bosch, A., López-Picazo, J. M., et al. (2002) · Oncology · doi:10.1159/000066520 · Cited by 127
Schackert, G., & Fidler, I. J. (1988) · PubMed · Cited by 117
Altered Expression of Angiopoietins During Blood-Brain Barrier Breakdown and Angiogenesis
Nourhaghighi, N., Teichert-Kuliszewska, K., Davis, J., Stewart, D. J., & Nag, S. (2003) · Laboratory Investigation · doi:10.1097/01.lab.0000082383.40635.fe · Cited by 115
Tóth, K., Vaughan, M. M., Peress, N. S., Slocum, H. K., & Rustum, Y. M. (1996) · PubMed Central · Cited by 114
Bertossi, M., Virgintino, D., Maiorano, E., Occhiogrosso, M., & Roncali, L. (1997) · Ultrastructural Pathology · doi:10.3109/01913129709023246 · Cited by 112
Quantitative study of microvessel ultrastructure in human peritumoral brain tissue
Stewart, P. A., Hayakawa, K., Farrell, C. L., & Maestro, R. F. D. (1987) · Journal of neurosurgery · doi:10.3171/jns.1987.67.5.0697 · Cited by 109
Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases
Dziadziuszko, R., Ardizzoni, A., Postmus, P. E., Smit, E. F., Price, A., Debruyne, C., LeGrand, C. C., & Giaccone, G. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00234-x · Cited by 108
The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice.
Gallo, J. M., Li, S., Guo, P., Reed, K., & Ma, J. (2003) · PubMed · Cited by 105
The Biology of Melanoma Brain Metastasis
Fidler, I. J., Schackert, G., Zhang, R.-D., Radinsky, R., & Fujimaki, T. (1999) · Cancer and Metastasis Reviews · doi:10.1023/a:1006329410433 · Cited by 102
Chemotherapy of brain metastases from lung carcinoma
Ushio, Y., Arita, N., Hayakawa, T., et al. (1991) · Neurosurgery · doi:10.1097/00006123-199102000-00005 · Cited by 98
Expression of multidrug-resistance P-glycoprotein (MDR1) in human brain tumors
Demeule, M., Shédid, D., Beaulieu, �., Maestro, R. F. D., Moghrabi, A., Ghosn, P., Moumdjian, R. A., Berthelet, F., & B�liveau, R. (2001) · International Journal of Cancer · doi:10.1002/ijc.1306 · Cited by 93
Chemotherapy of Brain Metastases from Lung Carcinoma: A Controlled Randomized Study
Ushio, Y., Arita, N., Hayakawa, T., et al. (1991) · Neurosurgery · doi:10.1227/00006123-199102000-00005 · Cited by 91
P-glycoprotein expression in brain tumors
Henson, J., Cordon‐Cardo, C., & Posner, J. B. (1992) · Journal of Neuro-Oncology · doi:10.1007/bf00170943 · Cited by 85
Simplified, noninvasive PET measurement of blood-brain barrier permeability.
Iannotti, F., Fieschi, C., Alfano, B., Picozzi, P., Mansi, L., Pozzilli, C., Punzo, A., del Vecchio, G., Lenzi, G. L., & Salvatore, M. (1987) · Journal of computer assisted tomography · doi:10.1097/00004728-198705000-00004 · Cited by 80
Giorgio, C. G., Giuffrida, D., Pappalardo, A., Russo, A. D., Santini, D., Salice, P., Blanco, G., Castorina, S., Failla, G., & Bordonaro, R. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2005.05.026 · Cited by 70
Fine, R. L., Chen, J., Balmaceda, C. M., Bruce, J. N., Huang, M., Desai, M., Sisti, M. B., McKhann, G. M., Goodman, R. R., Bertino, J., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2356 · Cited by 67
Self-citationSchackert, G., Simmons, R. D., Buzbee, T. M., Hume, D. A., & Fidler, I. J. (1988) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/80.13.1027 · Cited by 66
Angiogenesis, Metastasis, and Endogenous Inhibition
Kirsch, M., Schackert, G., & Black, P. M. (2000) · Journal of Neuro-Oncology · doi:10.1023/a:1006453428013 · Cited by 51
Lo, E. H., Pan, Y., Matsumoto, K., & Kowall, N. W. (1994) · Magnetic Resonance Imaging · doi:10.1016/0730-725x(94)92533-x · Cited by 47
Radiotherapy and chemotherapy of brain metastases
Soffietti, R., Costanza, A., Laguzzi, E., Nobile, M., & Rudà, R. (2005) · Journal of Neuro-Oncology · doi:10.1007/s11060-004-8096-3 · Cited by 43
Metastatic Tumors of the Nervous System
Taillibert, S., & Delattre, J. (2005) · Journal of Neuro-Oncology · doi:10.1007/s11060-004-8092-7 · Cited by 39
Somer, R. A., & Langer, C. J. (2005) · Cancer Investigation · doi:10.1081/cnv-200050449 · Cited by 2
Cited by
Challenges to curing primary brain tumours
Aldape, K., Brindle, K. M., Chesler, L., Chopra, R., Gajjar, A., Gilbert, M. R., Gottardo, N., Gutmann, D. H., Hargrave, D., Holland, E. C., et al. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0177-5 · Cited by 959
Falchook, G. S., Long, G. V., Kurzrock, R., Kim, K. B., Arkenau, T. H., Brown, M. P., Hamid, O., Infante, J. R., Millward, M., Pavlick, A. C., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60398-5 · Cited by 943
Lockman, P. R., Mittapalli, R. K., Taskar, K. S., Rudraraju, V., Gril, B., Bohn, K. A., Adkins, C. E., Roberts, A., Thorsheim, H. R., Gaasch, J. A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1564 · Cited by 693
Circadian Timing in Cancer Treatments
Lévi, F., Okyar, A., Dulong, S., Innominato, P. F., & Clairambault, J. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094626 · Cited by 476
Miller, D. S., Bauer, B., & Hartz, A. M. S. (2008) · Pharmacological Reviews · doi:10.1124/pr.107.07109 · Cited by 392
Metadata
- Authors
- Gerstner, E. R., & Fine, R. L.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-06-01
- Volume
- 25
- Issue
- 16
- Pages
- 2306-2312
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2095265260
- Cited by
- 265
- References
- 59
- FWCI
- 6.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.